Nebenwirkungen · Elrexfio
ELREXFIO 40 mg/mL solution for injection · Abschnitt 4.8 · PDF-Seite 13
HOS-150167 · Präparat HOS-100256
Cytokine release syndrome (CRS) CRS occurred in 57.9% of patients who received ELREXFIO at the recommended dosing schedule, with Grade 1 CRS in 43.7%, Grade 2 in 13.7% and Grade 3 in 0.5% of patients. Most patients experienced CRS after the first step-up dose (43.2%) or the second step-up dose (19.1%), with 7.1% of patients having CRS after the first full treatment dose and 1.6% of patients after a subsequent dose. Recurrent CRS occurred in 13.1% of patients. The median time to onset of CRS was 2 (range: 1 to 9) days after the most recent dose, with a median duration of 2 (range: 1 to 19 days) days.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T10:56:00Z · SHA-256 ec0f4a679d2a7d6174fef968d6a1f360599c3f73a460f0ffb9ca69435091340a · Passage 6bd2db3d7361a3e933698561ec82c68c297db4ff88453841291341d50db914fc · Zeichen 7622–8228 im Abschnitt